Plain-English translation of NCT06381739 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new COVID-19 vaccine called that is delivered by breathing it in as a fine mist, rather than by injection. Researchers want to see if this medication is safe and whether it helps your immune system build stronger protection against COVID-19, especially in your lungs where the virus first enters your body. The trial involves people who have already received at least three doses of the standard mRNA COVID vaccines.
Current COVID vaccines work well to prevent severe illness, but they don't always stop infection completely because new virus variants can escape the immune response. This medication is designed to boost your immune system's defenses directly in your lungs, the main site where COVID enters the body, which may provide stronger and longer-lasting protection against emerging variants.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new inhaled vaccine or a placebo (a mist with no active medication). You will breathe in the mist during a study visit and then return for follow-up appointments so researchers can check for any side effects and take blood samples to measure how your immune system responds. Some participants may also be asked to have a special airway sampling procedure to look at immune responses in the lungs.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Canada